ReviewMolecular medicine (Cambridge, Mass.)
Nonviral vector gene modification of stem cells for myocardial repair.
Review in Molecular medicine (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 35 citations in OpenAlex.
- Tadalafil, a long acting phosphodiesterase inhibitor, promotes bone marrow stem cell survival and their homing into ischemic myocardium for cardiac repair.Physiological reports · 2017Article
- Enhanced non-viral gene delivery by coordinated endosomal release and inhibition of β-tubulin deactylase.Nucleic acids research · 2017Article
- Optimizing stem cells for cardiac repair: Current status and new frontiers in regenerative cardiology.World journal of stem cells · 2017Review
- Functional polymers of gene delivery for treatment of myocardial infarct.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies.Advances in experimental medicine and biology · 2012Review
- Polymer transfected primary myoblasts mediated efficient gene expression and angiogenic proliferation.Journal of controlled release : official journal of the Controlled Release Society · 2010Article
- Assessment and optimization of cell engraftment after transplantation into the heart.Circulation research · 2010Review
- Stem cell paracrine actions and tissue regeneration.Regenerative medicine · 2010Review
- Angiomyogenesis for myocardial repair.Antioxidants & redox signaling · 2009Review
- Recent progress on tissue-resident adult stem cell biology and their therapeutic implications.Stem cell reviews · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic angiogenesis and myogenesis restore perfusion of ischemic myocardium and improve left ventricular contractility. These therapeutic modalities must be considered as complementary rather than competing to exploit their advantages for optimal beneficial effects. The resistant nature of cardiomyocytes to gene transfection can be overcome by ex vivo delivery of therapeutic genes to the heart using genetically modified stem cells. This review article gives an overview of different vectors and delivery systems in general used for therapeutic gene delivery to the heart and provides a critical appreciation of the ex vivo gene delivery approach using genetically modified stem cells to achieve angiomyogenesis for the treatment of infarcted heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.